SecBot SecBot
PRESS-RELEASE ·Filed May 6, 2026

URGN

UroGen Pharma Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

ZUSDURI's accelerating launch trajectory (109% QoQ) validates the blockbuster thesis and drives the beat. Watch for continued site-of-care expansion and repeat prescriber growth in Q2. The maintained JELMYTO guidance and controlled OpEx provide a clean setup. Key catalysts ahead: UGN-103 NDA submission (H2 2026) and AUA KOL panel on May 17.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.25
T+0 close · May 6, 2026 · via day close
Latest settled
+45.68%
T+60 · $38.24
Vs SPY
+43.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $26.25entry
  2. T+1 · 6mo ago +1.30%α +1.63% · $26.59
  3. T+5 · 6mo ago +13.52%α +12.39% · $29.80
  4. T+20 · 6mo ago +1.33%α −1.45% · $26.60
  5. T+60 · 4mo ago +45.68%α +43.62% · $38.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO growth ($21.7M, +7% YoY). Net loss narrowed to $23.6M ($0.47/share) from $43.8M ($0.92/share) a year ago, beating the consensus EPS estimate of -$0.48. The company maintained JELMYTO revenue guidance of $97-101M and operating expense guidance of $240-250M for 2026.

Key Financial Metrics

EPS
−$0.47
est −$0.48 · +2.1%
Revenue
$51.0M
est $44.8M · +13.8% · +151.6% YoY
Rating
beat
Guidance
$97M-$101M (JELMYTO only)
maintained
Gross Margin
91.9%

Key Facts

  • Total revenue $51.0M vs $20.3M YoY (+152%), beating consensus $44.8M
  • ZUSDURI net product revenue $29.2M in first full quarter of launch (109% QoQ growth)
  • JELMYTO revenue $21.7M (+7% YoY), in line with full-year guidance of $97-101M
  • Net loss $23.6M ($0.47/share) vs consensus -$0.48, a beat
  • Cash and equivalents $140.3M; $200M debt facility from Pharmakon refinanced existing debt
  • UGN-103 NDA submission on track for H2 2026; UGN-104 Phase 3 enrollment expected by end of 2026
  • 972 activated sites of care, 256 unique ZUSDURI prescribers as of March 31, 2026

Financial Impact

Revenue beat consensus by $6.2M (13.8%); EPS beat consensus by $0.01 (2.1%)

revenuenet losscash position

Risk Factors

  • ZUSDURI adoption may decelerate as early adopter pool saturates
  • SG&A expenses rose 47% YoY to $51.5M, outpacing revenue growth rate
  • Shareholders' deficit of $124.3M; reliance on debt financing for operations
  • UGN-103/104 clinical and regulatory timelines could slip

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3288758

Track record

16 reports on URGN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026